Active-ingredient Dossier
Buprenorphine
Active-ingredient Dossier for Buprenorphine (partial opioid agonist). Australian brands, products, PBS listings, PBAC outcomes — compiled by arcimedes.
- Brand: BUPREDERMAL
- Brand: BUVIDAL
- Brand: NORSPAN
- Brand: SUBLOCADE
- Brand: SUBOXONE FILM
- Brand: SUBUTEX
- Therapeutic area: Pain Management
- Therapeutic area: Psychiatry
- Therapeutic area: Oncology
What is
Buprenorphine Buprenorphine is a partial opioid agonist.
Australian brands containing
Buprenorphine — BUPREDERMAL — BUVIDAL — NORSPAN — SUBLOCADE — SUBUTEX — B-PATCH — BUPRENORPHINE SANDOZ — BUPRENORPHINE AUP
Therapeutic areas
Buprenorphine is registered across three therapeutic areas: Oncology (5 brands), Pain & Anaesthesia (2 brands), and Psychiatry (1 brand).
Sponsor landscape
Five sponsors market buprenorphine in Australia: AU Pharma, Mundipharma, Indivior, Sandoz, and Camurus.
PBS and regulatory activity
Five buprenorphine brands have PBS-listed items, with the latest PBS schedule date of 1 May 2026. In the 2024–25 financial year, PBS expenditure on buprenorphine was approximately $131.9 million across 1.55 million prescriptions. The latest PBAC outcome for buprenorphine was recorded on 1 November 2021. Four brands have PBAC outcomes on record, and no buprenorphine brands have published AusPARs.